{
    "id": 20840,
    "fullName": "TRIM24 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "TRIM24-BRAF results from the fusion of TRIM24 and BRAF, leads to increased Mek and Erk phosphorylation, but does not enhance proliferation and invasion in cell culture (PMID: 24345920, PMID: 30254212), and confers resistance to Raf inhibitors in culture (PMID: 24345920), and therefore, is predicted to lead to a gain of function. TRIM24-BRAF has been identified in melanoma (PMID: 24345920, PMID: 30254212).",
            "references": [
                {
                    "id": 5136,
                    "pubMedId": 24345920,
                    "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24345920"
                },
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 8805,
        "geneSymbol": "TRIM24",
        "terms": [
            "TRIM24",
            "hTIF1",
            "PTC6",
            "RNF82",
            "TF1A",
            "TIF1",
            "TIF1A",
            "TIF1ALPHA"
        ]
    },
    "variant": "TRIM24 - BRAF",
    "createDate": "04/08/2016",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 5658,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited downstream MAPK signaling in transformed human cells expressing TRIM24-BRAF in culture (PMID: 24345920).",
            "molecularProfile": {
                "id": 21339,
                "profileName": "TRIM24 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5136,
                    "pubMedId": 24345920,
                    "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24345920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7551,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 inhibited Erk signaling and anchorage-independent growth of transformed cells over expressing TRIM24 - BRAF in culture (PMID: 24727320).",
            "molecularProfile": {
                "id": 21339,
                "profileName": "TRIM24 - BRAF"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6416,
                    "pubMedId": 24727320,
                    "title": "Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24727320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5656,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) was incapable of suppressing MAPK signaling in transformed human cells expressing TRIM24-BRAF in culture (PMID: 24345920).",
            "molecularProfile": {
                "id": 21339,
                "profileName": "TRIM24 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5136,
                    "pubMedId": 24345920,
                    "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24345920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20706,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a TRIM24-BRAF fusion was detected in a non-small cell lung cancer patient harboring EGFR L858R with acquired resistance to Tagrisso (osimertinib) (PMID: 31911548).",
            "molecularProfile": {
                "id": 35296,
                "profileName": "TRIM24 - BRAF EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21339,
            "profileName": "TRIM24 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35296,
            "profileName": "TRIM24 - BRAF EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}